Ro - Telehealth for GLP1 Weight Management Ro.Co/PlusSideZ _________________________________________________________________________
What if millions of women with PCOS were misunderstood for years because the condition was treated mainly as a reproductive disorder instead of a metabolic disease tied to insulin resistance, obesity, hormones, and fertility?
In this episode of The Plus SideZ Podcast, Dr. Melanie Cree, a pediatric endocrinologist, obesity researcher, and PCOS/PMOS expert, explains the recent global consensus to rename PCOS to PMOS, or Polyendocrine Metabolic Ovarian Syndrome, to better reflect the condition’s metabolic and hormonal impact.
Dr. Cree breaks down how delayed diagnosis and outdated understanding may have prevented many patients from getting earlier metabolic treatment and intervention.
We discuss: Why so many women with PCOS were misunderstood or dismissed The connection between PCOS, PMOS, insulin resistance, obesity, and fertility
Why weight gain is not just about willpower
Adolescent PCOS and why early intervention matters
GLP-1 medications like semaglutide for PCOS/PMOS
Emerging research focused on ovulation, fertility, and metabolic health
How hormones, appetite, and metabolism are connected
Why the PMOS name change could improve diagnosis and treatment
Dr. Cree also shares information about her ongoing research and studies exploring how GLP-1 medications may help improve metabolic and reproductive health in people with PCOS/PMOS.
Learn more about studies https://medschool.cuanschutz.edu/pediatrics/sections/endocrinology/endocrinology-research/cree-lab/Cree-Melanie-UCD4665?utm_source=chatgpt.com
Podden och tillhörande omslagsbild på den här sidan tillhör
Kim Carlos. Innehållet i podden är skapat av Kim Carlos och inte av,
eller tillsammans med, Poddtoppen.
